Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

— ACPPPA  

Official title:

Study of the Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis in the West Indies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03832374
• Other study ID #: 15/E/27
• Status: Completed
• Start date: June 2, 2016
• Est. completion date: March 2022

Study information

• Verified date: March 2022
• Source: University Hospital Center of Martinique
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs.

The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways.

Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 77
• Est. completion date: March 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with rheumatoid arthritis ACR/EULAR 2010

• Patient with a higher age or equal to 18

• Patient receiving social security

• Patient giving his free and informed written consent

Exclusion Criteria:

• Patient with overlap syndrome with another autoimmune disease

• Patients with known severe cardiopulmonary pathology

• Woman who is pregnant and breast feeding

• Patient with language difficulties or understanding

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Other:
• Descriptive

Locations

Country	Name	City	State
Martinique	CHU Martinique	Fort-de-France

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Center of Martinique

Country where clinical trial is conducted

Martinique, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of the positivity of the anti citrullinated peptide antibodies and subtype	Presence of one or more subtypes of anti citrullinated peptide antibodies in the serum of patients with interstitial pneumopathy associated with rheumatoid arthritis who would be absent	three years
Secondary	Genetic analysis of the main mutations	Presence of mutation TERT, RTEL1, PARN et SFTPC	three years